[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fc1QXqFi0Jc47jrpCrr1lwMH9Q6oCujT8i0JUt6sHFLk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Jewish General Hospital",[4],95,false,14,4,257530,2,73,[14,17,19,22,24,26,28,31],{"name":15,"count":16},"Frailty",6,{"name":18,"count":16},"Quality of Life",{"name":20,"count":21},"Rectal Cancer",5,{"name":23,"count":9},"Low Anterior Resection Syndrome",{"name":25,"count":9},"Old Age",{"name":27,"count":9},"Emergencies",{"name":29,"count":30},"Social Isolation",3,{"name":32,"count":30},"Health Impairment",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05188222","Preoperative Maltodextrin's Effect on Cardiac Function in Cardiac Surgery","2026-12-01","Maltodextrin solution",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT07292142","FMT in Triple Negative Breast Cancer Guided by ctDNA","2029-12","Fecal Microbiota Transplantation",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,79,101,130,157,175,200,225,251,276,294,321,339,364,389,443,466,491,515,544,562,580,598,622,647],{"intervention":38,"totalTrials":53,"cells":54},1,{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":62,"PHASE4":64,"NA":77},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[],{"trials":63,"activeCount":57},[],{"trials":65,"activeCount":53,"soonestReadout":37},[66],{"nctId":35,"briefTitle":36,"status":67,"phases":68,"primaryCompletion":37,"completion":69,"start":70,"enrollment":71,"conditions":72,"interventions":76},"NOT_YET_RECRUITING",[49],"2027-03-01","2025-12-01",70,[73,74,75],"Left Ventricular Dysfunction","Quality of Recovery","Right Ventricular Dysfunction",[38],{"trials":78,"activeCount":57},[],{"intervention":43,"totalTrials":53,"cells":80},{"EARLY_PHASE1":81,"PHASE1":83,"PHASE2":85,"PHASE3":95,"PHASE4":97,"NA":99},{"trials":82,"activeCount":57},[],{"trials":84,"activeCount":57},[],{"trials":86,"activeCount":53,"soonestReadout":42},[87],{"nctId":40,"briefTitle":41,"status":67,"phases":88,"primaryCompletion":42,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},[46,47],"2031-12","2026-02",125,[93],"Breast Cancer",[43],{"trials":96,"activeCount":57},[],{"trials":98,"activeCount":57},[],{"trials":100,"activeCount":57},[],{"intervention":102,"totalTrials":53,"cells":103},"Vitamin D3",{"EARLY_PHASE1":104,"PHASE1":106,"PHASE2":108,"PHASE3":110,"PHASE4":112,"NA":128},{"trials":105,"activeCount":57},[],{"trials":107,"activeCount":57},[],{"trials":109,"activeCount":57},[],{"trials":111,"activeCount":57},[],{"trials":113,"activeCount":57},[114],{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":127},"NCT02999204","Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients","COMPLETED",[49],"2020-09-23","2020-10-01","2015-01",57,[124,125,126],"Renal Insufficiency, Chronic","Vascular Stiffness","Bone Diseases, Metabolic",[102],{"trials":129,"activeCount":57},[],{"intervention":131,"totalTrials":53,"cells":132},"Normal Saline Flush, 0.9% Injectable Solution_#1",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":141,"NA":155},{"trials":134,"activeCount":57},[],{"trials":136,"activeCount":57},[],{"trials":138,"activeCount":57},[],{"trials":140,"activeCount":57},[],{"trials":142,"activeCount":57},[143],{"nctId":144,"briefTitle":145,"status":117,"phases":146,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":153},"NCT02925858","Effect of Ketamine on Analgesia Post-Cardiac Surgery",[49],"2018-11-01","2018-11-27","2017-08-28",80,[152],"Pain, Postoperative",[131,154],"Ketamine Hydrochloride",{"trials":156,"activeCount":57},[],{"intervention":154,"totalTrials":53,"cells":158},{"EARLY_PHASE1":159,"PHASE1":161,"PHASE2":163,"PHASE3":165,"PHASE4":167,"NA":173},{"trials":160,"activeCount":57},[],{"trials":162,"activeCount":57},[],{"trials":164,"activeCount":57},[],{"trials":166,"activeCount":57},[],{"trials":168,"activeCount":57},[169],{"nctId":144,"briefTitle":145,"status":117,"phases":170,"primaryCompletion":147,"completion":148,"start":149,"enrollment":150,"conditions":171,"interventions":172},[49],[152],[131,154],{"trials":174,"activeCount":57},[],{"intervention":176,"totalTrials":53,"cells":177},"Oxytrol",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":184,"PHASE4":186,"NA":198},{"trials":179,"activeCount":57},[],{"trials":181,"activeCount":57},[],{"trials":183,"activeCount":57},[],{"trials":185,"activeCount":57},[],{"trials":187,"activeCount":57},[188],{"nctId":189,"briefTitle":190,"status":117,"phases":191,"primaryCompletion":192,"completion":192,"start":193,"enrollment":194,"conditions":195,"interventions":197},"NCT01899794","Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence.",[49],"2013-04","2007-10",66,[196],"Urinary Incontinence Mixed (Stress and Urge)",[176],{"trials":199,"activeCount":57},[],{"intervention":201,"totalTrials":53,"cells":202},"apixaban",{"EARLY_PHASE1":203,"PHASE1":205,"PHASE2":207,"PHASE3":209,"PHASE4":211,"NA":223},{"trials":204,"activeCount":57},[],{"trials":206,"activeCount":57},[],{"trials":208,"activeCount":57},[],{"trials":210,"activeCount":57},[],{"trials":212,"activeCount":57},[213],{"nctId":214,"briefTitle":215,"status":117,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT02672709","Apixaban in Hemodialysis",[49],"2016-08","2016-04",7,[221],"End-stage Renal Disease",[201],{"trials":224,"activeCount":57},[],{"intervention":226,"totalTrials":53,"cells":227},"Lidocaine",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":249},{"trials":229,"activeCount":57},[],{"trials":231,"activeCount":57},[],{"trials":233,"activeCount":57},[],{"trials":235,"activeCount":57},[],{"trials":237,"activeCount":57},[238],{"nctId":239,"briefTitle":240,"status":241,"phases":242,"primaryCompletion":243,"completion":244,"start":245,"enrollment":9,"conditions":246,"interventions":248},"NCT01433328","Lidocaine Subcutaneous Infusion for Control of Treprostinil Related Site Pain","TERMINATED",[49],"2012-03","2012-04","2012-01",[247],"Pulmonary Arterial Hypertension",[226],{"trials":250,"activeCount":57},[],{"intervention":252,"totalTrials":53,"cells":253},"HypotonicTreprostinil Solution",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":274},{"trials":255,"activeCount":57},[],{"trials":257,"activeCount":57},[],{"trials":259,"activeCount":57},[],{"trials":261,"activeCount":57},[],{"trials":263,"activeCount":57},[264],{"nctId":265,"briefTitle":266,"status":267,"phases":268,"primaryCompletion":269,"completion":269,"start":270,"enrollment":57,"conditions":271,"interventions":272},"NCT01615627","Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain","WITHDRAWN",[49],"2019-02-28","2012-07-01",[247],[252,273],"Eutonic Treprostinil Solution",{"trials":275,"activeCount":57},[],{"intervention":273,"totalTrials":53,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":284,"PHASE4":286,"NA":292},{"trials":279,"activeCount":57},[],{"trials":281,"activeCount":57},[],{"trials":283,"activeCount":57},[],{"trials":285,"activeCount":57},[],{"trials":287,"activeCount":57},[288],{"nctId":265,"briefTitle":266,"status":267,"phases":289,"primaryCompletion":269,"completion":269,"start":270,"enrollment":57,"conditions":290,"interventions":291},[49],[247],[252,273],{"trials":293,"activeCount":57},[],{"intervention":295,"totalTrials":53,"cells":296},"Parasternal blocks",{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":303,"PHASE4":317,"NA":319},{"trials":298,"activeCount":57},[],{"trials":300,"activeCount":57},[],{"trials":302,"activeCount":57},[],{"trials":304,"activeCount":57},[305],{"nctId":306,"briefTitle":307,"status":117,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":313,"interventions":315},"NCT05191745","Long-acting Parasternal Blocks for Analgesia After Cardiac Surgery",[48],"2023-04-28","2024-06-01","2022-01-26",60,[314],"Coronary Artery Bypass Graft Surgery",[295,316],"Standard of care",{"trials":318,"activeCount":57},[],{"trials":320,"activeCount":57},[],{"intervention":316,"totalTrials":53,"cells":322},{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":329,"PHASE4":335,"NA":337},{"trials":324,"activeCount":57},[],{"trials":326,"activeCount":57},[],{"trials":328,"activeCount":57},[],{"trials":330,"activeCount":57},[331],{"nctId":306,"briefTitle":307,"status":117,"phases":332,"primaryCompletion":309,"completion":310,"start":311,"enrollment":312,"conditions":333,"interventions":334},[48],[314],[295,316],{"trials":336,"activeCount":57},[],{"trials":338,"activeCount":57},[],{"intervention":340,"totalTrials":53,"cells":341},"Meaning-Making intervention",{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":348,"PHASE4":360,"NA":362},{"trials":343,"activeCount":57},[],{"trials":345,"activeCount":57},[],{"trials":347,"activeCount":57},[],{"trials":349,"activeCount":57},[350],{"nctId":351,"briefTitle":352,"status":117,"phases":353,"primaryCompletion":354,"completion":354,"start":355,"enrollment":356,"conditions":357,"interventions":359},"NCT02583932","Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer",[48],"2020-08","2015-10",179,[358],"Advanced Cancer",[340],{"trials":361,"activeCount":57},[],{"trials":363,"activeCount":57},[],{"intervention":365,"totalTrials":53,"cells":366},"68Ga-DOTATATE PET\u002FCT",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":373,"PHASE4":385,"NA":387},{"trials":368,"activeCount":57},[],{"trials":370,"activeCount":57},[],{"trials":372,"activeCount":57},[],{"trials":374,"activeCount":57},[375],{"nctId":376,"briefTitle":377,"status":117,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":384},"NCT02840149","SUV on 68Ga-DOTATATE PET\u002FCT and Ki-67 Index in Neuro-Endocrine Tumors",[48],"2023-12-13","2019-10-01",45,[383],"Neuroendocrine Tumors",[365],{"trials":386,"activeCount":57},[],{"trials":388,"activeCount":57},[],{"intervention":390,"totalTrials":9,"cells":391},"Ribavirin",{"EARLY_PHASE1":392,"PHASE1":394,"PHASE2":396,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":393,"activeCount":57},[],{"trials":395,"activeCount":57},[],{"trials":397,"activeCount":57},[398,409,418,427],{"nctId":399,"briefTitle":400,"status":117,"phases":401,"primaryCompletion":402,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":407},"NCT00559091","A Study of Ribavirin to Treat M4 and M5 Acute Myelocytic Leukemia",[47],"2010-02","2007-04",18,[406],"Acute Myelocytic Leukemia",[408],"ribavirin",{"nctId":410,"briefTitle":411,"status":241,"phases":412,"primaryCompletion":413,"completion":413,"start":414,"enrollment":9,"conditions":415,"interventions":417},"NCT01056757","Treatment With Ribavirin for Patients With Metastatic Breast Cancer",[46,47],"2010-11","2009-12",[416],"Metastatic Breast Cancer",[390],{"nctId":419,"briefTitle":420,"status":241,"phases":421,"primaryCompletion":422,"completion":422,"start":423,"enrollment":21,"conditions":424,"interventions":426},"NCT01309490","Phase I\u002FII Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients",[46,47],"2014-10-29","2011-03-17",[425],"Malignant Solid Tumor",[390],{"nctId":428,"briefTitle":429,"status":117,"phases":430,"primaryCompletion":121,"completion":121,"start":431,"enrollment":432,"conditions":433,"interventions":435},"NCT01056523","Use of Ribavirin and Low Dose Ara-C to Treat Acute Myeloid Leukemia",[46,47],"2010-01",29,[434],"Acute Myeloid Leukemia",[390,436],"Cytarabine arabinoside",{"trials":438,"activeCount":57},[],{"trials":440,"activeCount":57},[],{"trials":442,"activeCount":57},[],{"intervention":444,"totalTrials":53,"cells":445},"Metformin",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":460,"PHASE4":462,"NA":464},{"trials":447,"activeCount":57},[],{"trials":449,"activeCount":57},[],{"trials":451,"activeCount":57},[452],{"nctId":453,"briefTitle":454,"status":267,"phases":455,"primaryCompletion":456,"start":217,"enrollment":57,"conditions":457,"interventions":459},"NCT02042495","Endometrial Cancer Biomarker Changes Following Exposure to Metformin",[47],"2017-12",[458],"Endometrial Cancer",[444],{"trials":461,"activeCount":57},[],{"trials":463,"activeCount":57},[],{"trials":465,"activeCount":57},[],{"intervention":467,"totalTrials":53,"cells":468},"Gleevec and Chlorambucil",{"EARLY_PHASE1":469,"PHASE1":471,"PHASE2":473,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":470,"activeCount":57},[],{"trials":472,"activeCount":57},[],{"trials":474,"activeCount":57},[475],{"nctId":476,"briefTitle":477,"status":241,"phases":478,"primaryCompletion":479,"completion":479,"start":480,"enrollment":481,"conditions":482,"interventions":484},"NCT00558961","Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients",[46,47],"2009-04","2005-10",13,[483],"Chronic Lymphocytic Leukemia",[467],{"trials":486,"activeCount":57},[],{"trials":488,"activeCount":57},[],{"trials":490,"activeCount":57},[],{"intervention":492,"totalTrials":53,"cells":493},"INGAP Peptide, Ustekinumab",{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":498,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":495,"activeCount":57},[],{"trials":497,"activeCount":57},[],{"trials":499,"activeCount":57},[500],{"nctId":501,"briefTitle":502,"status":117,"phases":503,"primaryCompletion":504,"completion":504,"start":505,"enrollment":21,"conditions":506,"interventions":508},"NCT02204397","Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis",[47],"2017-03-08","2015-11",[507],"Type 1 Diabetes Mellitus",[492],{"trials":510,"activeCount":57},[],{"trials":512,"activeCount":57},[],{"trials":514,"activeCount":57},[],{"intervention":516,"totalTrials":53,"cells":517},"Ipilimumab",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":519,"activeCount":57},[],{"trials":521,"activeCount":57},[],{"trials":523,"activeCount":57},[524],{"nctId":525,"briefTitle":526,"status":527,"phases":528,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":533,"interventions":535},"NCT01676649","Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma","UNKNOWN",[47],"2017-02","2026-05","2012-11",30,[534],"Untreated Stage III Melanoma or Stage IV Melanoma",[516,536,537],"Carboplatin","Paclitaxel",{"trials":539,"activeCount":57},[],{"trials":541,"activeCount":57},[],{"trials":543,"activeCount":57},[],{"intervention":536,"totalTrials":53,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":547,"activeCount":57},[],{"trials":549,"activeCount":57},[],{"trials":551,"activeCount":57},[552],{"nctId":525,"briefTitle":526,"status":527,"phases":553,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":554,"interventions":555},[47],[534],[516,536,537],{"trials":557,"activeCount":57},[],{"trials":559,"activeCount":57},[],{"trials":561,"activeCount":57},[],{"intervention":537,"totalTrials":53,"cells":563},{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":574,"PHASE4":576,"NA":578},{"trials":565,"activeCount":57},[],{"trials":567,"activeCount":57},[],{"trials":569,"activeCount":57},[570],{"nctId":525,"briefTitle":526,"status":527,"phases":571,"primaryCompletion":529,"completion":530,"start":531,"enrollment":532,"conditions":572,"interventions":573},[47],[534],[516,536,537],{"trials":575,"activeCount":57},[],{"trials":577,"activeCount":57},[],{"trials":579,"activeCount":57},[],{"intervention":436,"totalTrials":53,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":592,"PHASE4":594,"NA":596},{"trials":583,"activeCount":57},[],{"trials":585,"activeCount":57},[],{"trials":587,"activeCount":57},[588],{"nctId":428,"briefTitle":429,"status":117,"phases":589,"primaryCompletion":121,"completion":121,"start":431,"enrollment":432,"conditions":590,"interventions":591},[46,47],[434],[390,436],{"trials":593,"activeCount":57},[],{"trials":595,"activeCount":57},[],{"trials":597,"activeCount":57},[],{"intervention":599,"totalTrials":53,"cells":600},"SarCNU",{"EARLY_PHASE1":601,"PHASE1":603,"PHASE2":614,"PHASE3":616,"PHASE4":618,"NA":620},{"trials":602,"activeCount":57},[],{"trials":604,"activeCount":57},[605],{"nctId":606,"briefTitle":607,"status":117,"phases":608,"completion":609,"start":610,"conditions":611,"interventions":613},"NCT00003703","Chemotherapy in Treating Patients With Advanced Solid Tumors",[46],"2004-03","1999-01",[612],"Unspecified Adult Solid Tumor, Protocol Specific",[599],{"trials":615,"activeCount":57},[],{"trials":617,"activeCount":57},[],{"trials":619,"activeCount":57},[],{"trials":621,"activeCount":57},[],{"intervention":623,"totalTrials":53,"cells":624},"Nitric Oxide",{"EARLY_PHASE1":625,"PHASE1":627,"PHASE2":629,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":626,"activeCount":57},[],{"trials":628,"activeCount":57},[],{"trials":630,"activeCount":57},[],{"trials":632,"activeCount":57},[],{"trials":634,"activeCount":57},[],{"trials":636,"activeCount":57},[637],{"nctId":638,"briefTitle":639,"status":527,"phases":640,"primaryCompletion":641,"completion":641,"start":642,"enrollment":643,"conditions":644,"interventions":646},"NCT04292483","Pulmonary Capillary Recruitment in Fontan Patients",[],"2023-12-31","2020-06-11",15,[645],"Congenital Heart Disease",[623],{"intervention":648,"totalTrials":53,"cells":649},"Nestle Resource",{"EARLY_PHASE1":650,"PHASE1":652,"PHASE2":654,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":651,"activeCount":57},[],{"trials":653,"activeCount":57},[],{"trials":655,"activeCount":57},[],{"trials":657,"activeCount":57},[],{"trials":659,"activeCount":57},[],{"trials":661,"activeCount":57},[662],{"nctId":663,"briefTitle":664,"status":117,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":669,"conditions":670,"interventions":672},"NCT02559635","Does Bowel Stimulation Before Loop Ileostomy Closure Reduce Postoperative Ileus?",[50],"2022-01-18","2022-07-18","2016-12-01",101,[671],"Postoperative Ileus",[648]]